Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q4 FY2022 Earnings Presentation
30 slides from Dishman Carbogen Amcis's earnings presentation, May 11, 2022
Slide 1: Cover letter to stock exchanges: investor presentation on audited results
Dishman Carbogen Amcis� Dishman Carbogen Amcis Ltd Dishman Corporate House 9 lscon-Bopal Road, Ambli, Ahmedabad - 380058 • Gujarat, India CIN:L74900GJ2007PLC051338 +9127 1742 0102 '- dishman@dishmangroup.com � 11th May, 2022 www.imdcal.com !$ To, To, Department of Corporate Services The Manager, BSE
Slide 2: Quarter ended March 31st, 2022
Quarter ended March 31st, 2022 May 2022
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
Dishman in a Nutshell 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIS in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
Past Performance at a Glance Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) 21,407 EBITDA EBITDA % 4,499 20,586 20,436 4,087 19,120 5,519 3,660 16,948 4,976 3,400 4,453 3,937 2,538 26.8% 24.3% 2,744 18.4% 26.3% 14.3% FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22^ FY18 FY19
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview 5
Slide 7: Quarter Highlights
Dishman Carbogen Amcis QUARTER
Slide 8: Q4 FY22 Result Highlights
Q4 FY22 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 5,293 5,621 5,690 1,095 884 843 16.7% 19.5% 14.8% Q4FY21 Q3FY22 Q4FY22 Q4FY21 Q3FY22 Q4FY22^ ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹ ) 10.8% 606 6.3 5.8% 4.9 4.5 2.0% 983 306 776 702 113 Q4FY21 Q3FY2
Slide 9: FY22 Result Highlights
FY22 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 3,937 21,407 4200 19,120 3700 3200 2,744 2700 2200 1700 1200 18.4% 700 14.3% 200 FY21 FY22 FY21 FY22^ ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹ ) 3,400 3700 26.0 7.5% 3200 24.0 2700 2,538 22.0 1,612 20.0
Slide 10: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q4 FY22 Q4 FY21 YoY % FY22 FY21 YoY % Income from Operations (Net) 5,689.9 5,293.2 7.5% 21,406.9 19,120.3 12.0% COGS 1,477.2 1,663.9 (11.2%) 4,474.2 4,681.50 (4.4%) Employee Expenses 2,525.9 2,197.7 14.9% 9,814.9 8,729.1 12.4% Other Expenses 1,466.9 548.
Slide 11: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Particulars (₹ mn) Mar-22 Mar-21 Particulars (₹ mn) Mar-22 Mar-21 Equity Share Capital 313.6 313.6 Property, plant and equipment 17,429.5 16,990.1 Capital Work in Progress 7,548.2 4,246.4 Other Equity 55,175.8 56,674.6 Right to use Lease Assets 2,891.1 3,178.1 Total - Shar
Slide 12: Segment Wise Revenue Analysis
SEGMENT WISE REVENUE ANALYSIS Revenues – Segment wise Breakup (₹ mn) Q4 FY22 Q4 FY21 YoY % FY22 FY21 YoY% CRAMS (% of total) 78.81% 73.09% 77.05% 74.92% CRAMS - India 484.7 226.5 114.0% 1,596.8 533.9 199.1% CRAMS - Switzerland, France & China 3,747.4 3,425.4 9.4% 13,707.8 12,804.2 7.1% CRAMS - UK 25
Slide 13: Segment Wise Revenue Break-up
SEGMENT WISE REVENUE BREAK-UP Total Operating Revenue – Q4 FY22 Total Operating Revenue – FY22 CRAMS – 78.81% Marketable Molecules – 21.19% CRAMS – 77.05% Marketable Molecules – 22.95% 9.7% 10.2% 5.6% 10.8% 8.6% 7.2% 1.6% 1.9% 37.7% 47.6% 52.4% 62.3% 71.8% 72.6% CRAMS - India CRAMS - Switzerland Car
Slide 14: Segment-wise Margin Analysis
SEGMENT-WISE MARGIN ANALYSIS EBITDA Margin* % Q4 FY22 Q4 FY21 FY22 FY21 CRAMS CRAMS- India - - - - CRAMS – Switzerland, France & China 14.7% 19.2% 18.7% 19.1% CRAMS - UK 13.8% 21.4% 17.6% 18.9% Marketable Molecules Carbogen Amcis BV 29.5% 34.9% 30.2% 34.5% Others 7.2% 18.3% 7.0% 15.5% *includes the
Slide 15: Adjusted EBITDA
ADJUSTED EBITDA (₹ Cr) Reason EBITDA Impact CGAM AG • Provision for CHF 2.46 mn for particles observed due to machine malfunction in few Other Expense 19.97 batches in the order of one of the customer Employee benefit expense • Provision for pension & leave due to last year salary base correction 12
Slide 16: Q4 & FY22 Result Highlights
Q4 & FY22 RESULT HIGHLIGHTS Net Revenue at Rs 5,689.9 mn in Q4 FY22 up by 7.5% YoY CRAMS revenue increased by 15.9% YoY primarily due to: CRAMS India revenue increased by 114.0% due to continuous increase in commercial supplies from India Marketable Molecules revenue decreased by 15.3% YoY primarily
Slide 17: Business Update – CRAMS NCE
BUSINESS UPDATE – CRAMS NCE Construction of the future dedicated manufacturing building for a Japanese Client for a novel oncology drug linker is progressing, this is well aligned with Customer program. Some advanced intermediated for a US customer has been out-licensed to other US customers We curr
Slide 18: Business & Plant Updates - India
BUSINESS & PLANT UPDATES - INDIA Continuous increase in order flow for commercial manufacturing for Bavla and Naroda facilities. Focus on engineering improvements, process redesigns and quality software implementation in order to improve efficiencies and compliances. Corrective Action Plan for EDQM
Slide 19: Company Overview
Dishman Carbogen Amcis COMPANY
Slide 20: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 21: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 22: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA Superior Chemistry Skills & Capabilities CARBOGEN AMCIS BV., CARBOGEN AMCIS Veenendaal, The Netherlands (Shanghai) Co. Ltd. 28 dedicated R&D labs with multiple shift R&D Chin
Slide 23: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 24: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES § Focus is on supporting the development process from bench to market § Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 25: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 26: Therapeutic Area Split
THERAPEUTIC AREA SPLIT DEVELOPMENT COMMERCIAL 22% 21% 28% 32% New Dev Commercials 4% 11% Projects FY22 FY22 4% 18% 17% 11% 14% 6% 6% 4% 4% Cancer ADC-Warhead/ADC Eyes Antibiotic Blood/Immunology Hormone/Metabolism Pain/Nerves Diabetes Various APIs Non-APIs/Intermediates 25
Slide 27: Industry Overview
Dishman Carbogen Amcis INDUSTRY
Slide 28: Top 20 Therapy Areas (US$ bn) - 2025
2025 Expected Global Spending by Therapy Areas Oncology & Immunology expected to dominate sales and grow by 9-12% CAGR through 2025 5-Yr CAGR 2021-2025 Oncologics 273 9-12% Immunology 175 9-12% Top 20 Therapy Areas (US$ bn) - 2025 Antidiabetics 148 4-7% Neurology 143 3-6% Cardiovascular 74 1-4% Anti
Slide 29: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent nearly half of global spending in 2025 and almost 60% of total spending in developed markets 59% 47% 45% 41% 37% 38% 35% 28% 29% 24% 21% 21% 17% 14% 9% 10% 2010 2015 2020 2025 Pharmerging Other Developed Global 10 Developed 28 Sourc
Slide 30: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Mr. Binay Sarda Global CFO Christensen IR Email: harshil.dalal@imdcal.com P: +91 22 4215 0210 Email: bsarda@christensenir.com
Dishman Carbogen Amcis — Q4 FY2022 Earnings Presentation on 6ix